Home / 2020 / June / 29

Daily Archives: June 29, 2020

WHO Chief: COVID Pandemic Accelerating, ‘Not Even Close to Being Over’

 

The World Health Organization (WHO) director general says the coronavirus pandemic is “not even close to being over” and that the outbreak is accelerating globally.

At his usual press briefing from Geneva Monday, Tedros Adhanom Ghebreyesus said that Tuesday marks six months since the U.N. health agency was first informed of a cluster of unusual pneumonia cases in China – the first indications of the coronavirus’ emergence.

“Six months ago, none of us could have imagined how our world and our lives would be thrown into turmoil by this new virus,” he said, noting WHO has since recorded more than 10 million cases and 500,000 deaths globally.

 

Tedros said most countries must ask how they plan to live with the coronavirus, calling it the “new normal.”

He said that while many countries have been successful in slowing the spread of the virus, they have not completely stopped it. He said that some countries have seen surges in the virus as they have attempted to reopen their societies and economies.

Tedros said that shows people are still susceptible, and the virus still has “room to move. The hard reality is this is not even close to being over…we’re all in this for the long haul.”

Tedros said WHO will be convening a meeting this week to assess the progress made in coronavirus research and reevaluate priorities moving forward as the pandemic continues.

Dozens of vaccine candidates are currently in early stages of testing and some may move into late stage testing this summer.

 

Source: Voice of America

 

COVID-19 Spreading in US Too Fast to Control, CDC Expert Says

 

The novel coronavirus is spreading too fast and across too many places in the United States to bring it under control, a top expert said Monday as some states set records for new cases every day.

“We have way too much virus across the country for that right now, so it’s very discouraging,” Dr. Anne Schuchat of the Centers for Disease Control and Prevention told The Journal of the American Medical Association.

Dr. Schuchat called the surge in new cases just “the beginning,” and said new cases are not being rapidly identified and isolated with proper contact tracing.

“I think there was a lot of wishful thinking around the country that, hey it’s summer. Everything’s going to be fine. We’re over this and we are not even beginning to be over this. There are a lot of worrisome factors about the last week or so,” she said.

 

Dr. Schuchat appealed to people to wear masks, practice social distancing and not to expect any kind of relief until there’s a vaccine.

The city of Jacksonville, Florida, where the Republican Party will hold its convention in August, said Monday it will require masks for all public locations.

State officials have also halted alcohol consumption at bars because of what Governor Ron DeSantis called “widespread noncompliance.”

New Jersey Gov. Phil Murphy said Monday that indoor dining will not resume as planned this week because of the threat of the virus.

The Trump administration has said only 4% of U.S. counties has seen a jump in new coronavirus cases. But according to the Associated Press, more than 20% of the U.S. population lives in those counties.

Arizona, California, Florida and Texas are among the states that have seen the biggest spike in new cases.

 

The United States is expected to be on the European Union’s list of countries whose citizens are barred from traveling there because of COVID-19.  Diplomats say Brazil, India and Russia are also expected to be on the list because of their high number of cases.

“This is not an exercise to be nice or unfriendly to other countries, this is an exercise of self-responsibility,” Spain’s foreign minister, Arancha Gonzalez Laya, told Spanish radio.

EU diplomats say the list will be revised every 14 days.

President Donald Trump suspended most European travelers from entering the United States in March.

Canadian Prime Minister Justin Trudeau said the worst of the coronavirus outbreak is over in Canada but urged citizens to stay alert.

“After a very challenging spring things are continuing to move in the right direction,” Trudeau said Monday. “What the situation we’re seeing in the United States and elsewhere highlights for us is that even as our economy is reopening, we need to make sure we are continuing to remain vigilant.”

Non-essential border crossings between the United States and Canada are set to expire on July 21. But it is unclear how Canada will react if the surge in cases in the United States continues.

Canadian-based Cirque du Soleil Entertainment Group filed for bankruptcy protection Monday after the coronavirus pandemic forced it to cancel shows and lay off about 95% of its performers and staff.

In New York, Broadway theaters that first closed in March because of the coronavirus outbreak will now remain shut through the end of the year.

The shutdown has meant temporarily closing 31 plays and musicals, and putting as many as 100,000 actors, musicians, dancers, stagehands, and other theater professionals out of work.

 

Source: Voice of America

Constellation Brands Announces Comprehensive Effort in Advancing Social Justice and Eliminating Systemic Racism

  • Commits to invest $100 million over 10 years in Black and minority-owned businesses to improve representation in the beverage alcohol industry
  • Contributes $1 million to Equal Justice Initiative in support of their mission in challenging racial and economic injustice in the U.S.
  • Commits to advancing company policies and practices, providing training for employees to eliminate bias, and continue to foster a safe and inclusive working environment for all

VICTOR, N.Y., June 29, 2020 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today its commitment to a multi-initiative social justice action plan aimed to achieve greater equity for African American/Black colleagues at Constellation, within the beverage alcohol industry, and within the communities they operate in.

“The conditions that have allowed systemic racism to persist in the U.S. have existed far too long,” said Bill Newlands, president and chief executive officer at Constellation Brands. “We categorically denounce bigotry, racism, and social injustice. They are clearly inconsistent with our company values and our commitment to embracing diversity and creating an inclusive environment where all employees feel safe, respected, and valued. We stand in solidarity with the Black community and we are committed to achieving meaningful and lasting change.”

Constellation Brands Ventures (CBV), the company’s corporate venture capital group, will invest $100 million in African American/Black and minority-owned businesses in the beverage alcohol space and adjacent categories by 2030 through a new program, Focus on Minority Founders. Data has shown that the venture capital ecosystem is starkly homogeneous. In a study of U.S. venture activity from 2013 through 2017, just 1% of VC-backed entrepreneurs were Black(1). “These businesses serve as the fabric of their respective communities and we must make it more equitable for them to access the capital needed to have a fighting chance at success,” said Newlands. “In a little over a year, CBV’s Focus on Female Founders initiative has shifted our Ventures portfolio mix from 20% female-owned to 50% female-owned. This reinforces there is a real need for these programs, and they can drive measurable improvement in minority representation for our industry.” In addition to funding, the Focus on Minority Founders initiative will support the growth and development of Black and minority-owned businesses by providing sales, marketing, operations, and finance expertise through the CBV team and Constellation’s many subject matter experts.

In support of societal reform, Constellation is entering a multi-year partnership with the Equal Justice Initiative (EJI). The partnership will include a contribution of $1 million to further EJI’s mission and provide training opportunities for Constellation leadership. Founded by Bryan Stevenson in 1989, EJI is committed to challenging racial and economic injustice, advocating for equal treatment in the criminal justice system, and protecting basic human rights for the most vulnerable in American society.

Also part of its action plan, Constellation is taking steps internally and within its extended network of business partners to create greater equity for African American/Black colleagues. The company is reviewing recruitment, hiring, and talent development practices to ensure African American/Black talent is supported and unconscious bias is addressed at all levels. The company is also evaluating brand engagements and advertising policies to ensure media partners, brand sponsorships, and other activations are aligned to brand and company values.  For example, true to its brand ethos of supporting and empowering all women, Kim Crawford has partnered with Black Girl Ventures, a non-profit providing greater access to funding and resources for Black and Brown female entrepreneurs and a stronger pathway for women of color to launch and grow their own business.

(1)  Rate My Investor, Diversity in U.S. Startups

ABOUT CONSTELLATION BRANDS
At Constellation Brands (NYSE: STZ and STZ.B), our mission is to build brands that people love because we believe sharing a toast, unwinding after a day, celebrating milestones, and helping people connect, are Worth Reaching For. It’s worth our dedication, hard work, and the bold calculated risks we take to deliver more for our consumers, trade partners, shareholders, and communities in which we live and work. It’s what has made us one of the fastest-growing large CPG companies in the U.S. at retail, and it drives our pursuit to deliver what’s next.

Today, we are a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Every day, people reach for our high-end, iconic imported beer brands such as Corona Extra, Corona Light, Corona Premier, Modelo Especial, Modelo Negra, and Pacifico, and our high-quality premium wine and spirits brands, including the Robert Mondavi Brand Family, Kim Crawford, Meiomi, The Prisoner Brand Family, SVEDKA Vodka, Casa Noble Tequila, and High West Whiskey.

But we won’t stop here. Our visionary leadership team and passionate employees from barrel room to boardroom are reaching for the next level, to explore the boundaries of the beverage alcohol industry and beyond. Join us in discovering what’s Worth Reaching For.

To learn more, follow us on Twitter @cbrands and visit www.cbrands.com.

MEDIA CONTACTS INVESTOR RELATIONS CONTACTS
Mike McGrew 773-251-4934 / michael.mcgrew@cbrands.com Patty Yahn-Urlaub 585-678-7483 / patty.yahn-urlaub@cbrands.com
Bob Czudak 585-678-7170 / bob.czudak@cbrands.com

A downloadable PDF copy of this news release enhanced with multimedia links can be found here: http://ml.globenewswire.com/Resource/Download/d2872adc-7b82-4414-bff3-bb65720fcd92

Philips expands its remote clinical collaboration offering based on the Reacts platform

June 29, 2020

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it is expanding its remote clinical collaboration and virtual training offerings across its portfolio, building on the IIT* (Innovative Imaging Technologies) Reacts collaborative platform. Leveraging innovative technologies, such as augmented reality, for remote virtual guidance, supervision and training, the platform provides unique interactive tools designed to meet the multi-faceted collaborative needs of healthcare professionals and patients.

“It is vital that we continue to advance our offering to help customers increase first-time-right diagnoses, by integrating innovations and technology that alleviate our customers’ pain points and streamline workflows,” said Bich Le, Business Leader Ultrasound at Philips. “With Reacts’ unique interactive tools we can provide secure expert solutions, and the training and support, needed for physicians to make definitive diagnostic decisions effectively and efficiently. This will enable us to accelerate our commitment to the patients we serve today as well as expanding access to imaging for new users and new use cases.”

The Reacts platform has already been deployed in more than 80 countries, across various disciplines in both clinical and educational settings. It allows healthcare professionals to interact remotely and dynamically in a wide range of applications, from teleconsultations, secure messaging, remote wound care and tele-ultrasound, to interactive telesurgical assistance and remote procedure supervision.

“Reacts addresses the clear and pressing need for secure remote collaboration and communication between healthcare providers and patients,” said Dr. Yanick Beaulieu, head of Clinical Science for Philips Ultrasound. “By deploying this interactive collaboration platform across Philips’ health technology solutions, we can change patient care models, expand telehealth capabilities, and accelerate technological developments in virtual collaboration globally.”

Since 2018, Reacts is integrated with the Philips’ Lumify point-of-care ultrasound solution, enabling users to share the live ultrasound stream from a Lumify device with a remote colleague on a mobile device, tablet or computer. This allows both parties to simultaneously view the live ultrasound image, as well as the webcam video stream, and provide real time feedback. Lumify with Reacts has proven to be a valuable tool for educational institutions, medical students and resident clinicians, EMS providers with long transit times, disaster relief providers, hospitals with satellite clinics, and clinicians seeking peer-to-peer collaboration for virtual guidance and training.

Lumify with Reacts can provide valuable diagnostic insight for front-line care providers to manage COVID-19-related lung and cardiac complications. Moreover, by enabling remote communication, Reacts reduces the need for physical interaction and can therefore help minimize the risk of virus transmission for medical teams. During the COVID-19 pandemic, Philips has also successfully piloted Reacts to provide case support during image-guided therapy procedures, remotely assisting clinicians as they diagnose and treat patients with coronary artery disease and other cardiovascular diseases. Philips will now further expand Reacts across its Diagnosis & Treatment portfolio.

* IIT Reacts is a wholly owned Philips subsidiary and part of Philips’ Ultrasound business.

Philips étend son offre en matière de collaboration clinique à distance avec la plateforme Reacts

Amsterdam, Pays-Bas – Royal Philips (NYSE: PHG, AEX: PHIA), leader mondial dans les technologies de santé, a annoncé aujourd’hui l’expansion de son offre en matière de collaboration et formation virtuelle en santé, avec la plateforme collaborative Reacts de TII* (Technologies innovatrices d’imagerie Inc.). Grâce à des technologies novatrices, telles que la réalité augmentée pour l’éducation à distance, la supervision et la guidance virtuelle, cette plateforme offre des outils interactifs uniques conçus pour répondre aux multiples besoins de collaboration à distance des professionnels de la santé et des patients.

“Il est essentiel que nous continuions à faire progresser notre offre afin d’aider nos clients à accroître la fiabilité du diagnostic en intégrant des innovations et des technologies qui atténuent les difficultés potentielles rencontrées lors des examens et qui améliorent l’efficacité des processus,” a déclaré Bich Le, Directrice Générale de Philips Ultrasound. “Grâce aux outils interactifs uniques de Reacts, nous pouvons fournir des solutions expertes sécurisées, ainsi que la formation et le soutien dont les médecins ont besoin pour prendre des décisions diagnostiques définitives de façon efficace. Cela nous permettra d’accélérer notre engagement envers les patients que nous servons aujourd’hui et d’élargir l’accès à l’imagerie à de nouveaux utilisateurs et de nouvelles utilisations.”

La plateforme Reacts est utilisée dans plus de 80 pays autant dans des contextes cliniques qu’éducatifs. Elle permet aux professionnels de la santé d’interagir à distance de façon dynamique pour un large éventail d’applications allant de téléconsultations, messagerie sécurisées, soins de plaies à distance et télé-échographie, à l’assistance télé-chirurgicale interactive et la supervision de procédures à distance.

“Reacts répond au besoin croissant de collaboration et de communication sécurisées à distance entre les professionnels de la santé et les patients,” a déclaré le Dr Yanick Beaulieu, Directeur des Sciences Cliniques chez Philips Ultrasound. “En déployant cette plateforme de collaboration interactive à travers les solutions de technologie de santé de Philips, nous pouvons changer les modèles de soins aux patients, étendre les capacités de télémédecine et accélérer les développements technologiques en matière de collaboration virtuelle à l’échelle mondiale.”

Depuis 2018, Reacts est intégrée à la solution d’échographie portable Lumify de Philips, permettant aux utilisateurs de partager en direct le flux vidéo de l’échographe Lumify en plus de partager de façon bidirectionnelle l’audio et le flux vidéo de la webcam. Cela permet à un professionnel effectuant une échographie avec le Philips Lumify, à partir d’une simple tablette ou téléphone intelligent, d’avoir accès à une expertise et une assistance virtuelles en temps réel, en collaborant à distance via Reacts avec un expert, peu importe où il se trouve dans le monde. Lumify avec Reacts s’est révélé un outil précieux pour aider les cliniciens à se connecter et à collaborer en temps réel comme jamais auparavant, sans barrière géographique. La solution peut notamment aider à optimiser les soins aux patients en permettant à des experts de superviser un examen échographique de façon virtuelle pour les établissements d’enseignement, les étudiants en médecine, les médecins résidents, les services médicaux d’urgence qui peuvent avoir de longs délais de transit, les services de secours en cas de catastrophe, les hôpitaux avec des cliniques satellites et les cliniciens qui cherchent à collaborer avec leurs pairs pour l’orientation et la formation virtuelles.

Lumify avec Reacts peut fournir des informations diagnostiques précieuses aux prestataires de soins de première ligne pour gérer les complications pulmonaires et cardiaques liées à la COVID-19. De plus, en permettant une communication à distance, Reacts réduit le besoin d’interaction physique et peut donc contribuer à minimiser le risque de transmission du virus pour les équipes médicales. Au cours de la pandémie de COVID-19, Philips a également mis Reacts à l’essai avec succès pour fournir une assistance virtuelle lors des procédures de thérapie guidée par imagerie, en aidant à distance les cliniciens à diagnostiquer et à traiter les patients atteints de coronaropathie et autres maladies cardiovasculaires. Philips étendra maintenant l’utilisation de Reacts à travers tout son portfolio de solutions de diagnostic et traitement.

* TII est une filiale à part entière de Philips et fait partie de la division Philips Ultrasound.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 15213446
E-mail: ben.zwirs@philips.com

Anna Hogrebe
Philips Global Press Office
Tel.: +1 416 270 6757
E-mail: anna.hogrebe@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

A propos de Royal Philips
Royal Philips (NYSE : PHG, AEX : PHIA) est une société de technologies médicales de pointe qui se consacre à l’amélioration de la santé des personnes et à l’obtention de meilleurs résultats dans tout le continuum de la santé, de la vie en bonne santé, de la prévention au diagnostic, jusqu’au traitement et aux soins à domicile. Philips s’appuie sur une technologie de pointe et sur une connaissance approfondie du milieu médical et des consommateurs pour proposer des solutions intégrées. Basée aux Pays-Bas, la société est un leader dans le domaine de l’imagerie diagnostique, de la thérapie guidée par l’image, du monitorage des patients et de l’informatique de santé, ainsi que dans le domaine de la santé des consommateurs et des soins à domicile. Philips a réalisé en 2019 un chiffre d’affaires de 19,5 milliards d’euros et emploie environ 81.000 personnes, avec des ventes et des services dans plus de 100 pays. Vous trouverez des informations sur Philips à l’adresse suivante: www.philips.com/newscenter.

Attachments

Novavax Expands Executive Leadership and Announces Key Promotions

GAITHERSBURG, Md., June 29, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Ben Machielse as Executive Vice President, CMC, with responsibility for overseeing Novavax’ manufacturing, process technology, quality and regulatory functions. The Company also announced several leadership promotions:

  • John J. Trizzino to Executive Vice President, Chief Business Officer and Chief Financial Officer
  • John A. Herrmann III, to Executive Vice President, Chief Legal Officer
  • Jill Hoyt to Executive Vice President, Chief Human Resources Officer

“Ben’s extensive manufacturing and operations expertise will be vital to our leadership team as we evolve to commercial stage,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “The addition of Ben supports our continued commitment to progressing our pipeline programs as we scale up to produce a global supply of NVX-CoV2373, our COVID-19 vaccine candidate, and grow our NanoFlu production capabilities. In addition, I also want to congratulate John, John, and Jill on their promotions as they are all a critical part of Novavax’ growth.”

Mr. Machielse brings more than 25 years of biotechnology industry experience to Novavax. He was most recently Chief Executive Officer of rare disease company Vtesse, before its acquisition by Sucampo Pharmaceuticals, Inc., now a part of Mallinckrodt. Previously, he was Chief Operating Officer at Omthera Pharmaceuticals, where he oversaw development and approval of a treatment for hypertriglyceridemia and was integral to the Company’s IPO and acquisition by AstraZeneca. Earlier, as Executive Vice President of Operations for MedImmune, later acquired by AstraZeneca, he led worldwide development and operations of the company’s therapeutic antibodies, small molecules and vaccine products. Additionally, he was responsible for development of MedImmune’s H1N1 influenza vaccine, which was the first to be approved by FDA. He currently sits on the board of directors of Comet Therapeutics, Complexa Therapeutics and Polyneuron. Mr. Machielse received a bachelor of science degree in medical biology and a master of science degree in biochemistry from the University of Utrecht in the Netherlands.

“The rapid and precise steps Novavax is taking to increase manufacturing capacity for NVX-CoV2373 demonstrate both the validity and the viability of our program as a significant part of the world’s COVID-19 vaccine solution,” said Mr. Machielse. “I am excited to work with the team as we rapidly advance development activities and manufacturing capabilities and ensure we deliver safe, innovative vaccines to prevent a broad range of infectious diseases worldwide.”

Mr. Trizzino originally joined Novavax in 2009 with responsibility for business development. In 2011, Mr. Trizzino joined Immunovaccine as its CEO and successfully led the company into clinical development of its lead candidate. In 2014, Mr. Trizzino rejoined Novavax and in 2018 was promoted to Chief Business Officer and Chief Financial Officer. Prior to his tenure at Novavax, Mr. Trizzino held leadership roles at several companies focused on infectious disease, including MedImmune, later acquired by AstraZeneca, ID Biomedical, acquired by GSK, and Henry Schein, Inc. Mr. Trizzino received a bachelor of science degree from Long Island University, CW Post and a master of business administration degree from New York University, Stern School of Business.

Mr. Herrmann has been our general counsel and corporate secretary since 2010, and will now also lead corporate and business development. Prior to joining Novavax, Mr. Herrmann was General Counsel at Ore Pharmaceuticals and Deputy General Counsel at Gene Logic before it became Ore Pharmaceuticals. He has also served as Senior Corporate Counsel for Celera Genomics and Baxter Healthcare. Mr. Herrmann received a bachelor of arts degree from Brown University and a juris doctorate from the University of Illinois.

Ms. Hoyt joined Novavax in 2008 with responsibility for human resources. Since joining the company, she has played a key role in expansion of the company’s talent base and geographic footprint, including the acquisition of manufacturing subsidiaries in Europe. She has held senior positions in HR at a number of technology companies, including TRW and Choicepoint. Ms. Hoyt received a bachelor of science degree in business administration from Shepherd University and a master of science degree in human resource management from Marymount University.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including statements regarding the manufacturing of vaccine antigen dose amounts and timing, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (SEC) and updated by any Quarterly Report on Form 10-Q, particularly the risks inherent to developing novel vaccines. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:
Investors
Novavax, Inc.
Silvia Taylor and Erika Trahan
ir@novavax.com
240-268-2022

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659

Novavax Expands Executive Leadership and Announces Key Promotions

GAITHERSBURG, Md., June 29, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Ben Machielse as Executive Vice President, CMC, with responsibility for overseeing Novavax’ manufacturing, process technology, quality and regulatory functions. The Company also announced several leadership promotions:

  • John J. Trizzino to Executive Vice President, Chief Business Officer and Chief Financial Officer
  • John A. Herrmann III, to Executive Vice President, Chief Legal Officer
  • Jill Hoyt to Executive Vice President, Chief Human Resources Officer

“Ben’s extensive manufacturing and operations expertise will be vital to our leadership team as we evolve to commercial stage,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “The addition of Ben supports our continued commitment to progressing our pipeline programs as we scale up to produce a global supply of NVX-CoV2373, our COVID-19 vaccine candidate, and grow our NanoFlu production capabilities. In addition, I also want to congratulate John, John, and Jill on their promotions as they are all a critical part of Novavax’ growth.”

Mr. Machielse brings more than 25 years of biotechnology industry experience to Novavax. He was most recently Chief Executive Officer of rare disease company Vtesse, before its acquisition by Sucampo Pharmaceuticals, Inc., now a part of Mallinckrodt. Previously, he was Chief Operating Officer at Omthera Pharmaceuticals, where he oversaw development and approval of a treatment for hypertriglyceridemia and was integral to the Company’s IPO and acquisition by AstraZeneca. Earlier, as Executive Vice President of Operations for MedImmune, later acquired by AstraZeneca, he led worldwide development and operations of the company’s therapeutic antibodies, small molecules and vaccine products. Additionally, he was responsible for development of MedImmune’s H1N1 influenza vaccine, which was the first to be approved by FDA. He currently sits on the board of directors of Comet Therapeutics, Complexa Therapeutics and Polyneuron. Mr. Machielse received a bachelor of science degree in medical biology and a master of science degree in biochemistry from the University of Utrecht in the Netherlands.

“The rapid and precise steps Novavax is taking to increase manufacturing capacity for NVX-CoV2373 demonstrate both the validity and the viability of our program as a significant part of the world’s COVID-19 vaccine solution,” said Mr. Machielse. “I am excited to work with the team as we rapidly advance development activities and manufacturing capabilities and ensure we deliver safe, innovative vaccines to prevent a broad range of infectious diseases worldwide.”

Mr. Trizzino originally joined Novavax in 2009 with responsibility for business development. In 2011, Mr. Trizzino joined Immunovaccine as its CEO and successfully led the company into clinical development of its lead candidate. In 2014, Mr. Trizzino rejoined Novavax and in 2018 was promoted to Chief Business Officer and Chief Financial Officer. Prior to his tenure at Novavax, Mr. Trizzino held leadership roles at several companies focused on infectious disease, including MedImmune, later acquired by AstraZeneca, ID Biomedical, acquired by GSK, and Henry Schein, Inc. Mr. Trizzino received a bachelor of science degree from Long Island University, CW Post and a master of business administration degree from New York University, Stern School of Business.

Mr. Herrmann has been our general counsel and corporate secretary since 2010, and will now also lead corporate and business development. Prior to joining Novavax, Mr. Herrmann was General Counsel at Ore Pharmaceuticals and Deputy General Counsel at Gene Logic before it became Ore Pharmaceuticals. He has also served as Senior Corporate Counsel for Celera Genomics and Baxter Healthcare. Mr. Herrmann received a bachelor of arts degree from Brown University and a juris doctorate from the University of Illinois.

Ms. Hoyt joined Novavax in 2008 with responsibility for human resources. Since joining the company, she has played a key role in expansion of the company’s talent base and geographic footprint, including the acquisition of manufacturing subsidiaries in Europe. She has held senior positions in HR at a number of technology companies, including TRW and Choicepoint. Ms. Hoyt received a bachelor of science degree in business administration from Shepherd University and a master of science degree in human resource management from Marymount University.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including statements regarding the manufacturing of vaccine antigen dose amounts and timing, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (SEC) and updated by any Quarterly Report on Form 10-Q, particularly the risks inherent to developing novel vaccines. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:
Investors
Novavax, Inc.
Silvia Taylor and Erika Trahan
ir@novavax.com
240-268-2022

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659

DHL Aviation to Standardize Electronic Communication for Air Freight Transportation with Descartes’ Global Air Messaging Gateway

WATERLOO, Ontario, June 29, 2020 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Brussels-based DHL Aviation has selected Descartes’ Global Air Messaging Gateway as its preferred platform to standardize electronic messaging with its global customer base, including major freight-forwarding organizations, other airlines, postal service operators and express courier companies, as well as ground handling agents (GHAs).

DHL will also deploy Descartes Air Shipment Management (ASM)™ to simplify its electronic document management for air shipments, and Descartes AEI™, an on-demand solution, to collect, prepare and submit the required advance electronic information for global air cargo security filings to a growing range of countries worldwide.

Based upon the Descartes Global Logistics Network™ (Descartes GLN™), Descartes’ Global Air Messaging Gateway solutions help carriers, like DHL Aviation, speed connectivity to trading partners, monitor shipment status in real-time, and communicate timely status updates to forwarders, GHAs and consignees. An industry-leading solution for multimodal, inter-enterprise electronic data exchange, the Descartes GLN provides members with a wide array of value-added services that span the entire shipment management process including contract management, freight booking, shipment tracking, and security filings.

“We’re pleased to expand our relationship with DHL, adding DHL Aviation to the growing list of carriers using Descartes’ solutions to enhance air freight communication with supply chain participants,” said Jos Nuijten, VP of Network Integration Strategy at Descartes. “For over 20 years, Descartes has helped carriers across the globe shift to more electronic processes and we remain committed to advancing solutions to further automate and improve communications in the air cargo industry.”

About DHL Aviation

DHL Aviation represents the airline of DHL Express, a division of Deutsche Post DHL Group. The Group is the world’s leading logistics company. The Group connects people and markets and is an enabler of global trade. It aspires to be the first choice for customers, employees and investors worldwide. To this end, Deutsche Post DHL Group is focusing on growth in its profitable core logistics businesses and accelerating the digital transformation in all business divisions. The Group contributes to the world through sustainable business practices, corporate citizenship and environmental activities. By the year 2050, Deutsche Post DHL Group aims to achieve zero emissions logistics. Deutsche Post DHL Group is home to two strong brands: DHL offers a comprehensive range of parcel and international express service, freight transport, and supply chain management services, as well as e-commerce logistics solutions. Deutsche Post is Europe’s leading postal and parcel service provider. Deutsche Post DHL Group employs approximately 550,000 people in over 220 countries and territories worldwide. The Group generated revenues of more than 63 billion Euros in 2019. The logistics company for the world.

About Descartes

Descartes (Nasdaq:DSGX) (TSX:DSG) is the global leader in providing on-demand, software-as-a-service solutions focused on improving the productivity, performance and security of logistics-intensive businesses. Customers use our modular, software-as-a-service solutions to route, schedule, track and measure delivery resources; plan, allocate and execute shipments; rate, audit and pay transportation invoices; access global trade data; file customs and security documents for imports and exports; and complete numerous other logistics processes by participating in the world’s largest, collaborative multimodal logistics community. Our headquarters are in Waterloo, Ontario, Canada and we have offices and partners around the world. Learn more at www.descartes.com, and connect with us on LinkedIn and Twitter.

Global Media Contact
Cara Strohack
Tel: +1 519-746-8110 ext. 202025
cstrohack@descartes.com

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ solution offering and potential benefits derived therefrom; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities commissions across Canada including Descartes most recently filed management’s discussion and analysis. If any such risks actually occur, they could materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.